MX2018001992A - Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors. - Google Patents
Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors.Info
- Publication number
- MX2018001992A MX2018001992A MX2018001992A MX2018001992A MX2018001992A MX 2018001992 A MX2018001992 A MX 2018001992A MX 2018001992 A MX2018001992 A MX 2018001992A MX 2018001992 A MX2018001992 A MX 2018001992A MX 2018001992 A MX2018001992 A MX 2018001992A
- Authority
- MX
- Mexico
- Prior art keywords
- phosphoinositide
- kinase inhibitors
- heterocyclic compounds
- tricyclic heterocyclic
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
The invention relates to a compound of formula I: (I) or a pharmaceutically acceptable salt thereof and/or stereoisomers thereof. The compounds of the invention are useful in therapy.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1514754.9A GB201514754D0 (en) | 2015-08-19 | 2015-08-19 | Compounds |
PCT/GB2016/052581 WO2017029521A1 (en) | 2015-08-19 | 2016-08-19 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018001992A true MX2018001992A (en) | 2018-06-19 |
Family
ID=54258853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018001992A MX2018001992A (en) | 2015-08-19 | 2016-08-19 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors. |
Country Status (9)
Country | Link |
---|---|
US (1) | US10442815B2 (en) |
EP (1) | EP3337807A1 (en) |
JP (1) | JP2018528942A (en) |
CN (1) | CN108349988B (en) |
AU (1) | AU2016307889A1 (en) |
CA (1) | CA2995909A1 (en) |
GB (1) | GB201514754D0 (en) |
MX (1) | MX2018001992A (en) |
WO (1) | WO2017029521A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5746172B2 (en) | 2009-08-20 | 2015-07-08 | カルス セラピューティクス リミテッド | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
EP3668839B1 (en) | 2017-08-17 | 2023-04-12 | Board of Regents, The University of Texas System | Heterocyclic inhibitors of atr kinase |
EP4069699A1 (en) | 2019-12-05 | 2022-10-12 | Verge Analytics, Inc. | Fused tricyclic heterocyclic compounds as inhibitors of pikfyve kinase useful for the treatment of neurological diseases |
WO2022169882A1 (en) | 2021-02-03 | 2022-08-11 | Verge Analytics, Inc. | Methods and treatment of viral infection caused by sars-cov-2 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1445742A1 (en) | 1963-11-06 | 1968-12-19 | Bayer Ag | Process for the preparation of 2-position substituted benzoxazinones |
US4017500A (en) | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
US5703075A (en) | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
JP3649395B2 (en) | 2000-04-27 | 2005-05-18 | 山之内製薬株式会社 | Fused heteroaryl derivatives |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
CA2414468A1 (en) | 2000-06-30 | 2002-01-10 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
ES2400339T3 (en) | 2002-07-15 | 2013-04-09 | Symphony Evolution, Inc. | Compounds, pharmaceutical compositions thereof and their use in the treatment of cancer |
FR2846657B1 (en) | 2002-11-05 | 2004-12-24 | Servier Lab | NOVEL PYRIDOPYRIMIDINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
CN1922171B (en) | 2004-02-26 | 2012-10-17 | Aska制药株式会社 | Pyrimidine derivative |
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
CN101228161B (en) | 2005-05-20 | 2012-10-10 | 沃泰克斯药物股份有限公司 | Pyrrolopyridines useful as inhibitors of protein kinase |
WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
KR20090021155A (en) | 2006-04-26 | 2009-02-27 | 에프. 호프만-라 로슈 아게 | Pyrimidine derivatives as pi3k inhibitors |
AR060632A1 (en) | 2006-04-26 | 2008-07-02 | Genentech Inc | PHOSFOINOSITIDE INHIBITING COMPOUNDS 3- KINASE AND METHODS OF USE |
EP2035436B1 (en) * | 2006-06-26 | 2011-05-25 | UCB Pharma S.A. | Fused thiazole derivatives as kinase inhibitors |
JP5313909B2 (en) | 2006-11-13 | 2013-10-09 | アイコス コーポレイション | Thienopyrimidinone for the treatment of inflammatory diseases and cancer |
NZ578744A (en) | 2007-01-31 | 2012-02-24 | Vertex Pharma | 2-aminopyridine derivatives useful as kinase inhibitors |
EP2139332A4 (en) * | 2007-03-28 | 2010-04-21 | Merck Sharp & Dohme | Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators |
US20100179143A1 (en) | 2007-05-29 | 2010-07-15 | Smithkline Beecham Corporation | Naphthyridine, derivatives as p13 kinase inhibitors |
GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
CA2732087A1 (en) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Substituted naphthyridines and their use as medicaments |
CA2742550A1 (en) | 2008-10-03 | 2010-04-08 | Merck Serono S.A. | 4-morpholino-pyrido[3,2-d]pyrimidines |
GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
US8981087B2 (en) | 2009-07-29 | 2015-03-17 | Karus Therapeutics Limited | Benzo [E] [1,3] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors |
JP5746172B2 (en) * | 2009-08-20 | 2015-07-08 | カルス セラピューティクス リミテッド | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
US20110207736A1 (en) | 2009-12-23 | 2011-08-25 | Gatekeeper Pharmaceuticals, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
GB201007347D0 (en) | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
SI2736895T1 (en) | 2011-07-27 | 2016-03-31 | Astrazeneca Ab | 2-(2,4,5-substituted-anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
KR20150087850A (en) | 2012-11-20 | 2015-07-30 | 제넨테크, 인크. | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
RS57816B1 (en) | 2013-05-10 | 2018-12-31 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors |
RU2019134551A (en) | 2013-05-30 | 2019-11-22 | Инфинити Фармасьютикалз, Инк. | TREATING MALIGNANT TUMORS USING MODULATORS OF PI3-KINASE ISOFORM |
EP3052494B1 (en) | 2013-06-28 | 2018-12-26 | H. Hoffnabb-La Roche Ag | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
WO2015054355A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma |
GB201321738D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
GB201321728D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321730D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201321729D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
GB201402431D0 (en) * | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
GB201514756D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compound and method of use |
GB201514751D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
-
2015
- 2015-08-19 GB GBGB1514754.9A patent/GB201514754D0/en not_active Ceased
-
2016
- 2016-08-19 EP EP16756767.6A patent/EP3337807A1/en not_active Withdrawn
- 2016-08-19 WO PCT/GB2016/052581 patent/WO2017029521A1/en active Application Filing
- 2016-08-19 US US15/753,358 patent/US10442815B2/en active Active
- 2016-08-19 CN CN201680058333.7A patent/CN108349988B/en active Active
- 2016-08-19 CA CA2995909A patent/CA2995909A1/en not_active Abandoned
- 2016-08-19 JP JP2018508666A patent/JP2018528942A/en not_active Withdrawn
- 2016-08-19 MX MX2018001992A patent/MX2018001992A/en unknown
- 2016-08-19 AU AU2016307889A patent/AU2016307889A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US10442815B2 (en) | 2019-10-15 |
US20180244685A1 (en) | 2018-08-30 |
EP3337807A1 (en) | 2018-06-27 |
AU2016307889A1 (en) | 2018-03-08 |
CN108349988A (en) | 2018-07-31 |
CA2995909A1 (en) | 2017-02-23 |
WO2017029521A1 (en) | 2017-02-23 |
JP2018528942A (en) | 2018-10-04 |
GB201514754D0 (en) | 2015-09-30 |
CN108349988B (en) | 2021-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
MX2018001992A (en) | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors. | |
PH12017501817A1 (en) | Heterocyclic compounds as lsd1 inhibitors | |
PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
PH12017500276A1 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
PH12018500040A1 (en) | Indazole and azaindazole compounds as irak-4 inhibitors | |
SA518400547B1 (en) | Pyrazolopyrimidine Derivatives as Kinase Inhibitor | |
MD20160106A2 (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as IRAK4 inhibitors | |
MY202022A (en) | Pyrrolotriazine compounds as tam inhibitors | |
MD20160118A2 (en) | Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as IDO1 inhibitors | |
MX2017006266A (en) | Heteroaryl compounds as irak inhibitors and uses thereof. | |
MX2017015740A (en) | Ror gamma (ror?) modulators. | |
PH12015502611A1 (en) | Heterocyclic compounds as hedgehog signaling pathway inhibitors | |
MX2017015741A (en) | Ror gamma (ror?) modulators. | |
MX2017015739A (en) | Ror gamma (rory) modulators. | |
MA39866A (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
MA40250A (en) | Quinolizinone derivatives as pi3k inhibitors | |
MX2016013265A (en) | Analogues of 4h-pyrazolo[1,5-î]benzimidazole compound as parp inhibitors. | |
PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
PH12019502046A1 (en) | Pyrrolotriazine derivatives as kinase inhibitor | |
SV2016005317A (en) | DERIVATIVES OF PIRROLIDINE -2,5-DIONA, PHARMACEUTICAL COMPOSITIONS AND METHODS TO USE AS IDO1 INHIBITORS | |
MA39993A (en) | Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors |